MetaCap

Rein Therapeutics (RNTX) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Telomir Pharmaceuticals (TELO) has outperformed Rein Therapeutics (RNTX) over the past year, losing 71.6% versus a loss of 77.2%. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNTX-77.24%TELO-71.56%
+32%-25%-82%
Nov 21, 20251 yearNov 20, 2026
RNTX-92.98%TELO-92.72%
+92%-5%-102%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNTX versus TELO key metrics
MetricRNTXTELO
Share price$0.3369$0.364
Market cap$29.06M$26.82M
1-day change-8.38%-17.24%
YTD return-70.96%-72.63%
1-year return-77.24%-71.56%
5-year return-97.47%—
EPS (TTM)$-1.51$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-49.87M$-10.41M
52-week high$2.10$1.58
52-week low$0.284$0.353
Distance from 52-week high-83.96%-76.96%
Analyst consensusnonenone
Avg. price target upside+1680.94%+998.90%
Average volume586.68K126.14K
Shares outstanding86.27M73.68M
Employees10—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

RNTX vs TELO FAQ

Which is bigger, Rein Therapeutics or Telomir Pharmaceuticals?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, RNTX or TELO?

TELO returned -71.56% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Rein Therapeutics and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons